Longwall Venture Partners

OrganOx is a medical device company focused on organ preservation and transplantation, specializing in normothermic preservation technology that mimics physiological conditions to protect livers before transplantation. The company develops and manufactures systems that continuously perfuse livers at body temperature with oxygenated blood, nutrients, and controlled pressures and flows to reduce decay, support bile production, glucose metabolism, and pH stability. Its Metra device stores livers outside the body at normal body temperature, enabling testing and transplantation. OrganOx was founded in 2008 and is based in Oxford, United Kingdom. The technology aims to improve transplant outcomes by maintaining organ viability during storage and enabling more flexible transplantation timelines.

Biofidelity Ltd., established in 2019 and based in Cambridge, UK, specializes in the research and development of molecular diagnostic assays. These assays are designed to rapidly detect specific DNA sequences, with a focus on applications in oncology, prenatal testing, infectious diseases, and organ transplant monitoring. The company's mission is to enhance and prolong patients' lives through early disease detection and targeted treatments.

Founded in 2019, Wayland Additive specializes in developing, manufacturing, and distributing metal additive manufacturing 3D printing machines. The company serves industries such as aerospace and medical, offering advanced solutions like electron beam lithography.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in drug discovery through advanced microfluidic technology. The company focuses on developing new therapies and innovative products by leveraging its unique platform, which allows for the precise and flexible control of thousands of droplets. This capability enables the combination of various cells, reporters, and reagents to conduct complex workflows without manual cell manipulation. By collaborating with major pharmaceutical companies and leading academic institutions, Lightcast Discovery seeks to enhance complex cell analysis and facilitate the discovery of new clinical approaches.

Founded in 2019, Wayland Additive specializes in developing, manufacturing, and distributing metal additive manufacturing 3D printing machines. The company serves industries such as aerospace and medical, offering advanced solutions like electron beam lithography.

Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.

MicrofluidX Ltd is a London-based company established in 2018 that specializes in developing a cell bioprocessing platform specifically designed for autologous cell and gene therapy manufacturing. The company offers a microfluidic bioprocessing system that integrates various cell culture capabilities—including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting—into a single closed system. This automated technology addresses key challenges in the field, such as process control, scalability, and cost, enabling biologists to efficiently conduct process development by experimenting with multiple cell culture conditions.

MIRICO Ltd. is a laser spectroscopy instrumentation company based in Oxford, founded in 2015 as a spin‑out from the STFC Rutherford Appleton Laboratory. It develops high‑performance gas‑sensing products that use laser dispersion, tunable laser absorption, and isotope‑ratio techniques to provide real‑time, in‑situ monitoring of trace gases and isotopologues. The instruments are applied in space exploration, planetary landers, environmental monitoring, atmospheric emissions, geochemistry, medical diagnostics, and oil‑and‑gas exploration and production. The company’s cloud‑connected platform delivers autonomous, continuous measurements in all weather conditions, enabling detection, localisation, and quantification of emissions to support net‑zero targets and operational optimisation.

Helio Display Materials is a developer of innovative perovskite-based materials aimed at enhancing display technology. The company focuses on creating materials that enable brighter and more colorful displays while significantly reducing power consumption. By leveraging metal halide perovskites, which can be synthesized using low-temperature processes and earth-abundant precursor materials, Helio aims to produce vibrant and efficient light-emitting technologies for televisions and displays. The company emphasizes collaboration with scientific and industry experts to expedite research and development, ensuring a strong scientific foundation for its intellectual property. Helio's mission is to improve display performance and efficiency, ultimately providing a superior visual experience.

Founded in 2019, Wayland Additive specializes in developing, manufacturing, and distributing metal additive manufacturing 3D printing machines. The company serves industries such as aerospace and medical, offering advanced solutions like electron beam lithography.

Closed Loop Medicine designs and develops healthcare technology software that optimizes drug dosing on an individual level through integrated digital therapies. The company focuses on improving patient outcomes for chronic diseases, with products in development for hypertension and insomnia.

Iothic is a developer of a decentralized platform that specializes in providing end-to-end, post-quantum resistant authentication and encryption solutions. The company's technology focuses on enabling secure, scalable, and robust authentication techniques that are compatible across various operating systems, communication protocols, and Internet of Things (IoT) stacks. By facilitating point-to-point quantum-resistant authentication, Iothic allows network providers to efficiently establish autonomous authentication services for a range of applications, from simple sensor networks to complex IoT systems. This innovation positions Iothic as a key player in enhancing security and interoperability in decentralized network environments.

Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.

Kinomica is a United Kingdom based medicine research and diagnostics company that develops KScan, a phosphoproteomic diagnostic platform designed to measure intracellular kinase activity and cell signaling pathways in cells and tissues. The platform supports the selection of targeted therapies by providing direct activity measurements of multiple endogenous kinases and comprehensive signaling network coverage, enabling clinicians to tailor treatment decisions for cancer patients and other conditions. By combining proprietary bioinformatics with phosphoproteomics, Kinomica identifies biomarkers and assesses pharmacodynamic responses to inform drug targeting and biomarker strategies. The company was founded in 2016 and is based in Macclesfield, United Kingdom.

MicrofluidX Ltd is a London-based company established in 2018 that specializes in developing a cell bioprocessing platform specifically designed for autologous cell and gene therapy manufacturing. The company offers a microfluidic bioprocessing system that integrates various cell culture capabilities—including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting—into a single closed system. This automated technology addresses key challenges in the field, such as process control, scalability, and cost, enabling biologists to efficiently conduct process development by experimenting with multiple cell culture conditions.

LettUs Grow develops aeroponic irrigation and farm management technology for greenhouse and vertical farming. The company designs modular, nozzle-free aeroponic systems that deliver nutrient mist to plant roots and are paired with automated control software to optimize conditions for individual species, while enabling pesticide-free operation. Its hardware and software aim to reduce labor, improve efficiency, and lower costs, with environmental benefits such as reduced waste and carbon footprint. Founded in 2015 and based in Bristol, United Kingdom, LettUs Grow markets solutions that support sustainable indoor farming.

Founded in 2019, Wayland Additive specializes in developing, manufacturing, and distributing metal additive manufacturing 3D printing machines. The company serves industries such as aerospace and medical, offering advanced solutions like electron beam lithography.

Closed Loop Medicine designs and develops healthcare technology software that optimizes drug dosing on an individual level through integrated digital therapies. The company focuses on improving patient outcomes for chronic diseases, with products in development for hypertension and insomnia.

Verdel Instruments Ltd specializes in the development of two-dimensional mass spectrometry (2DMS) equipment aimed at structural analysis and sequencing. Founded in 2018 and headquartered in Coventry, United Kingdom, the company provides advanced mass spectrometry technology that is utilized in analytical laboratories for the identification of key components and impurities in biopharmaceuticals, food, chemical products, and environmental samples. Its innovative technology allows for the fragmentation of various molecules while maintaining a correlation between each fragment and its precursor, significantly enhancing the structural elucidation process. This capability enables researchers to obtain comprehensive fragmentation datasets in seconds on standard bench-top mass spectrometers.

Closed Loop Medicine designs and develops healthcare technology software that optimizes drug dosing on an individual level through integrated digital therapies. The company focuses on improving patient outcomes for chronic diseases, with products in development for hypertension and insomnia.

Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.

Founded in 2013, Oxford Space Systems specializes in developing and manufacturing innovative deployable hardware structures for space environments. The company's products include deployable panels/hinge systems, composite linear boom systems, and deployable antennas, designed to be lighter, less complex, and lower cost than traditional alternatives. With a team of experienced professionals and backing from venture capital funds, Oxford Space Systems has successfully completed government co-developments and commercial contracts with leading satellite builders worldwide.

MIRICO Ltd. is a laser spectroscopy instrumentation company based in Oxford, founded in 2015 as a spin‑out from the STFC Rutherford Appleton Laboratory. It develops high‑performance gas‑sensing products that use laser dispersion, tunable laser absorption, and isotope‑ratio techniques to provide real‑time, in‑situ monitoring of trace gases and isotopologues. The instruments are applied in space exploration, planetary landers, environmental monitoring, atmospheric emissions, geochemistry, medical diagnostics, and oil‑and‑gas exploration and production. The company’s cloud‑connected platform delivers autonomous, continuous measurements in all weather conditions, enabling detection, localisation, and quantification of emissions to support net‑zero targets and operational optimisation.

Closed Loop Medicine designs and develops healthcare technology software that optimizes drug dosing on an individual level through integrated digital therapies. The company focuses on improving patient outcomes for chronic diseases, with products in development for hypertension and insomnia.

Base4 specializes in advancing state-of-the-art technologies for single-molecule analysis. The company is dedicated to developing innovative microdroplet-based sequencing technology that enables pathogen screening and DNA analysis. This technology generates long reads from individual DNA molecules without requiring initial amplification, providing users with the ability to understand and predict diseases more effectively. Base4's solutions aim to produce cheaper, more accurate, and meaningful sequencing data for large populations at a reduced cost.

Arquer Diagnostics Ltd. is a diagnostics company specializing in the design, development, and commercialization of non-invasive immunoassay diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring specific substances in body fluids, including a CE-marked ELISA kit for Mcm5, which is used in hospital pathology laboratories. Additionally, Arquer provides a point-of-care system that includes a robust reader instrument and disposable cartridges, facilitating the use of its tests in urology clinics, hospital laboratories, and general practice surgeries. Founded in 2005 and based in Sunderland, United Kingdom, Arquer Diagnostics aims to enhance cancer diagnosis and monitoring through its innovative technology, which detects a protein linked to the MCM5 gene, improving the accuracy and reliability of test results for patients and clinicians.

OxSonics Therapeutics develops a proprietary platform, SonoTran®, designed to enhance the efficacy and reduce toxicity of anti-cancer agents in solid tumours. The technology increases drug dose and distribution within tumours without requiring drug reformulation, fitting seamlessly into existing clinical workflows and providing real-time visualisation.

Keit Ltd. is a company specializing in the design and manufacture of advanced spectrometers and related instruments, catering to a wide range of applications from ultraviolet to far infrared rays. Incorporated in 2012 and headquartered in Didcot, United Kingdom, Keit is known for its innovative microFTS® design, a Fourier Transform Infrared (FTIR) spectrometer that is notably smaller, lighter, and more rugged than existing systems. Originally developed for space applications, the microFTS® is capable of operating in extreme environments and sets a new standard for real-time liquid-state analyses across various industries, including Pharmaceutical, Chemical, Oil & Gas, and Food & Beverage. Keit's products are also utilized for measuring signal levels, near line vibrations, and analyzing gas or liquid-borne species.

MIRICO Ltd. is a laser spectroscopy instrumentation company based in Oxford, founded in 2015 as a spin‑out from the STFC Rutherford Appleton Laboratory. It develops high‑performance gas‑sensing products that use laser dispersion, tunable laser absorption, and isotope‑ratio techniques to provide real‑time, in‑situ monitoring of trace gases and isotopologues. The instruments are applied in space exploration, planetary landers, environmental monitoring, atmospheric emissions, geochemistry, medical diagnostics, and oil‑and‑gas exploration and production. The company’s cloud‑connected platform delivers autonomous, continuous measurements in all weather conditions, enabling detection, localisation, and quantification of emissions to support net‑zero targets and operational optimisation.

User Replay Limited is a company that specializes in digital customer experience analytics software solutions. Founded in 2009 and headquartered in Reading, United Kingdom, it provides an integrated customer experience platform that leverages machine learning to help businesses discover and address issues in customer interactions. User Replay’s software tracks users' journeys on websites, identifying conversion barriers such as usability issues, technical problems, and confusing business logic. By analyzing the impact of these barriers on conversion rates, the platform enables targeted user experience improvements that can lead to measurable increases in sales. The company's solutions, which also support enhanced customer service and fraud prevention, are utilized by over 20 prominent brands across various sectors, including financial services, insurance, retail, and travel, in markets throughout the United States, United Kingdom, Europe, and beyond.

Oxford Cancer Biomarkers is a company focused on the development and commercialization of a range of biomarker tests specifically for colorectal cancer, aimed at enhancing personalized medicine in oncology. Closely associated with the Institute of Cancer Medicine at Oxford University, where its founders conduct leading research in translational cancer science, the company has established partnerships with pharmaceutical firms to leverage its discovery platforms, CancerNav and ToxNav, in creating companion diagnostic tests for emerging drugs. The tests provided by Oxford Cancer Biomarkers assess dihydropyridine dehydrogenase deficiency, identify variants linked to partial dihydropyrimidine deficiency, and evaluate the risk of potential toxicity, allowing healthcare providers to analyze resected tissue samples and predict relapse risk for patients more effectively.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Arquer Diagnostics Ltd. is a diagnostics company specializing in the design, development, and commercialization of non-invasive immunoassay diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring specific substances in body fluids, including a CE-marked ELISA kit for Mcm5, which is used in hospital pathology laboratories. Additionally, Arquer provides a point-of-care system that includes a robust reader instrument and disposable cartridges, facilitating the use of its tests in urology clinics, hospital laboratories, and general practice surgeries. Founded in 2005 and based in Sunderland, United Kingdom, Arquer Diagnostics aims to enhance cancer diagnosis and monitoring through its innovative technology, which detects a protein linked to the MCM5 gene, improving the accuracy and reliability of test results for patients and clinicians.

Sensiia Limited is a company based in Cambridge, United Kingdom, that specializes in the manufacture of sensor-based fertility wearable devices. Its flagship product, DuoFertility, is designed to track and predict female ovulation cycles while providing personalized support from fertility experts. This innovative system identifies the most fertile window up to 10 days in advance, allowing users to plan their schedules with greater confidence. DuoFertility has been clinically validated, demonstrating effectiveness comparable to that of an IVF cycle. Founded in 2006 and formerly known as Cambridge Temperature Concepts Limited, Sensiia focuses on delivering a natural and data-driven approach to fertility management, leveraging continuous monitoring and analytics to enhance user outcomes in reproductive health.

Momentum Bioscience develops rapid in vitro diagnostic tests for critically important clinical specimens. Its technologies include ETGA, which provides ultrasensitive, rapid, and universal detection of all bacterial and fungal species while identifying only viable organisms. Through Enzyme Mediated Amplification, the company aims to rapidly detect infections in blood and other normally sterile body fluids, enabling universal detection of viable bacteria and fungi in under two hours, far faster than conventional methods. The company offers a suite of related systems for rapid detection of infection in neonatal, emergency, and critical-care settings. Momentum Bioscience was established in 2005 and is based in Cardiff, United Kingdom.

Founded in 2013, Oxford Space Systems specializes in developing and manufacturing innovative deployable hardware structures for space environments. The company's products include deployable panels/hinge systems, composite linear boom systems, and deployable antennas, designed to be lighter, less complex, and lower cost than traditional alternatives. With a team of experienced professionals and backing from venture capital funds, Oxford Space Systems has successfully completed government co-developments and commercial contracts with leading satellite builders worldwide.

Oxford PV is a company based in Oxford, United Kingdom, founded in 2010 by Henry Snaith and Kevin Arthur. It specializes in the development and commercialization of thin-film perovskite solar cells, which are designed to be printed directly onto silicon solar cells, CIGS solar cells, or glass. The company's innovative technology enhances photovoltaic performance by efficiently capturing specific parts of the solar spectrum, providing a low-cost and lightweight alternative for energy generation. Oxford PV aims to contribute significantly to the growth of renewable energy globally through its advanced solar cell solutions.

OrganOx is a medical device company focused on organ preservation and transplantation, specializing in normothermic preservation technology that mimics physiological conditions to protect livers before transplantation. The company develops and manufactures systems that continuously perfuse livers at body temperature with oxygenated blood, nutrients, and controlled pressures and flows to reduce decay, support bile production, glucose metabolism, and pH stability. Its Metra device stores livers outside the body at normal body temperature, enabling testing and transplantation. OrganOx was founded in 2008 and is based in Oxford, United Kingdom. The technology aims to improve transplant outcomes by maintaining organ viability during storage and enabling more flexible transplantation timelines.

Crysalin Limited is a research and development company based in London, United Kingdom, founded in June 2007. It specializes in crysalin lattice technology, which has been developed from patented research conducted at the Oxford University Laboratory of Molecular Biophysics since 2002. The company's primary focus is on crysalins, a protein-based nanotechnology that significantly enhances protein structure determination, particularly for challenging macromolecular targets such as membrane proteins and flexible soluble proteins. By imposing order on these complex structures, crysalins enable advanced imaging techniques like X-ray and electron microscopy to accurately resolve three-dimensional molecular structures. In addition to protein structure determination, Crysalin's technology holds potential applications in biosensor development and optoelectronics, expanding its impact in the field of molecular research.

Diamond Microwave Devices Ltd. specializes in the development of semiconductor devices utilizing chemical vapor deposition (CVD) diamond technology. Founded in 2006 and headquartered in Leeds, United Kingdom, the company focuses on creating devices that serve both civil and defense applications, particularly in microwave power amplifiers and transmitters. As a subsidiary of Element Six (Pty) Ltd., Diamond Microwave Devices is positioned at the forefront of innovation in high-performance microwave technology.